Immunome (IMNM)
(Delayed Data from NSDQ)
$10.59 USD
+0.07 (0.67%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $10.60 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMNM 10.59 +0.07(0.67%)
Will IMNM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMNM
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
IMNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy
Other News for IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IMNM Stock News
Bullish Two Hundred Day Moving Average Cross - IMNM
September 19th Options Now Available For Immunome (IMNM)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IMNM Stock News
Immunome Elects New Directors at Annual Meeting